Jul 22, 2014
CTI BioPharma receives Israeli approval for aggressive B-cell non-Hodgkin's lymphoma therapy
CTI BioPharma receives Israeli approval for aggressive B-cell non-Hodgkin’s lymphoma therapy
Pixantrone
BBR-2778 , CTK0H5262
Pixolti
Pixuvri
UNII-P0R64C4CR9
An immunosuppressant.
144510-96-3 [RN]
5,8-Bis((2-aminoethyl)amino)-2-aza-anthracene-9,10-dione
6,9-Bis((2-aminoethyl)amino)benz(g)isoquinoline-5,10-dione
5,8-Bis((2-aminoethyl)amino)-2-aza-anthracene-9,10-dione
6,9-Bis((2-aminoethyl)amino)benz(g)isoquinoline-5,10-dione
CTI BioPharma receives Israeli approval for aggressive…
View On WordPress